A Phase 4 interventional study of Hecolin and Hepa-B in Hepatitis E Infection, sponsored by Norwegian Institute of Public Health. Completed at 1 site in Bangladesh. Open to female participants aged 16 Years to 39 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-08-15.
Sponsored by Norwegian Institute of Public Health · Phase 4, Interventional, and Prevention
The aim of the study is to determine the effectiveness of hepatitis E virus vaccine given in women of child bearing age in preventing HEV disease during pregnancy among women in rural Bangladesh.
Hepatitis E virus (HEV) infection is endemic in Bangladesh, causing severe or fatal complications in pregnant women. This GLOBVAC funded project aims to assess the safety, feasibility, acceptability, immunogenicity, effectiveness, and cost-effectiveness of the HEV vaccine (Hecolin, Innovax, China) when given women of childbearing age in a rural area in Bangladesh (Matlab). The vaccine has been shown to be both effective and safe in the general adult population in China, but there is insufficient data about its efficacy among pregnant women, the group with most to gain from vaccination.
The research plan has been carefully designed and will be conducted by a multidisciplinary team of researchers at International Centre for Diarrhoeal Disease Research (iccdr,b) in Bangladesh and the Norwegian Institute of Public Health and Innlandet Hospital Trust in Norway. Over a period of 2 years, 20,745 non-pregnant women will be recruited and will receive either the hepatitis E vaccine or a hepatitis B vaccine (control group). All women who develop hepatitis E symptoms will be tested for the disease. Those who become pregnant during the study will also be checked and tested during regular home visits. Clinical outcomes and vaccine adverse events will be closely monitored.
In order to evaluate the initial safety profile and immunogenicity of the vaccine, a pilot study was completed during summer 2017. A total of 100 non-pregnant females and males, aged 16-39, were enrolled and randomly received either the hepatitis E vaccine or a hepatitis B vaccine. Participants were vaccinated on day 0 and day 30, and blood, dried blood spots (DBS) and saliva samples were collected on day 0 and day 60 for use in laboratory assay validation and serological and cellular immunogenicity analyses. Following each vaccination, home visits were carried out for 7 days to record adverse reactions. No serious adverse reactions were observed, and only a few mild local adverse reactions were recorded which all resolved without sequela. Preliminary immunogenicity results, showed that 44 participants had seroconverted (HEV), after just two doses of the vaccine. Furthermore, during this pilot study the implementation of protocols and procedures for all stages of the trial were tested in preparation for the start of the main trial.
Additionally, hepatitis surveillance in Matlab has been initiated in order to establish an HEV surveillance system. All women aged 16-39 are included in the surveillance, and requested to contact icddr,b staff if they experience jaundice of any duration, or other symptoms of hepatitis. Patients admitted to Matlab hospital have a blood sample taken for hepatitis diagnostics, and acute HEV cases are investigated virologically, clinically and immunologically. Household visits occur bi-weekly to document any possible hepatitis cases.
37 studies on the registry are indexed under Hepatitis E; 9 are open to participants now.
This study's enrollment of 19,460 is above the median of 330 across 26 interventional studies indexed under Hepatitis E.
Browse Hepatitis E studies →Norwegian Institute of Public Health is the lead sponsor of 51 studies on the registry; 8 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Hecolin, 0.6 ml intramuscular injection day 0, 1 month and 6 months.
Drug: Hecolin
Hepa-B, 1 ml intramuscular injection day 0, 1 month and 6 months.
Drug: Hepa-B
0.6ml Hecolin vaccine im. on day 0, 1 month and 6 months.
Also known as: HEV 239
1ml Hepa-B vaccine im. on day 0, 1 month and 6 months.
Also known as: Hepatitis B virus (HBV) vaccine
Effectiveness of HEV vaccine in preventing HEV diseases among women in Bangladesh
To determine the effectiveness of hepatitis E virus (HEV) vaccine in preventing HEV disease during pregnancy among women in rural Bangladesh
Time frame: 2 years
To determine the safety of HEV vaccine in Bangladeshi women of childbearing age
Number of participants with adverse events related to vaccination as assessed by CTCAE v4.0
Time frame: 2 years
To determine the immunogenicity of HEV vaccine in Bangladeshi women of childbearing age
Number of participants who seroconvert after three doses
Time frame: 2 years
Effectiveness of HEV vaccine in preventing HEV disease in non-pregnant Bangladeshi women of childbearing age
To determine the effectiveness of hepatitis E virus (HEV) vaccine in preventing HEV disease in participants
Time frame: 2 years
Estimate serological correlates of protection
Assess the anti-HEV IgG levels before and one month after the last dose of vaccine for primary vaccine response and record if any HEV disease occurs.
Time frame: 2 years
Assess the feasibility, acceptability and cost-effectiveness of HEV vaccination of women of childbearing age in rural Bangladesh
Analyse cost per disability, adjusted life year and quality adjusted life year
Time frame: 2 years
Investigate acute HEV cases virologically, clinically and immunologically in relation to outcome.
Examine acute HEV cases in relation to severity of illness and immunological responses
Time frame: 2 years
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Undecided
Ran from Oct 2017 to primary completion in Sep 2019, 23 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Hecolin
Norwegian Institute of Public Health